Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.
The global professional services firm reported 6% organic revenue growth for the second consecutive year, fueled by its Aon United strategy and strategic acquisitions like NFP. With $7 billion in available capital, Aon is poised to accelerate investments in high-growth areas, notably the burgeoning data center and alternative capital markets.
Despite reporting earnings that edged past expectations, Houlihan Lokey's shares fell 12% post-earnings. Analysts' long-term forecasts remain largely unchanged, signaling a 'steady-as-she-goes' assessment of the investment bank's prospects.
Southside Bancshares (SBSI) reported a significant rebound in fourth-quarter earnings, driven by strategic repositioning of its securities portfolio and lower funding costs. While loan growth remained modest, executives outlined a cautious outlook for near-term margin improvement and detailed plans for technology investments and selective M&A in competitive Texas markets.
LPL Financial Holdings Inc. (LPLA) reported robust fourth-quarter results, reaching a milestone $2.4 trillion in advisory and brokerage assets. Adjusted earnings per share grew 23%, driven by strategic execution and the integration of Commonwealth Financial.
Arthur J. Gallagher & Co. reported robust fourth-quarter results, driven by a potent mix of organic expansion and strategic acquisitions like AssuredPartners. Management projects sustained mid-single-digit growth for 2026, backed by a significant capital reserve for further mergers and acquisitions.
Hong Kong-listed construction firm Affluent Foundation Holdings (SEHK:1757) has unveiled plans to enter the regulated financial services sector, sending its shares on a meteoric rise. As the stock trades at a significant premium, analysts question whether the market is pricing in future success or overlooking execution risks.
A new analysis commissioned by TikTok challenges conventional ad measurement, arguing that high ROI doesn't always equal sales growth, and that premium, engaging formats often deliver superior business outcomes despite higher costs.
Despite a recent earnings miss, Charles Schwab's stock has significantly outpaced the market over the past year. Wall Street maintains a cautiously optimistic stance, with upgraded ratings and bullish price targets pointing to further potential gains.
As the U.S. renewable energy sector builds on a record-breaking 2025, it faces a critical juncture defined by supply chain pressures, extreme weather, and evolving market rules. Strategic adaptation, not just growth, will determine its sustainable trajectory.
Thai troops now occupy a shell-damaged compound in O'Smach, Cambodia, which officials identify as a former hub for international scam operations. A military-led tour revealed a labyrinth of soundproofed call centers, fake police stations, and meticulous scripts, shedding light on a multi-billion dollar criminal enterprise.
A KKR-led group is finalizing a deal to acquire Singapore-based data centre operator STT GDC, a move that underscores the intense global competition for digital infrastructure assets as AI-driven demand surges across Asia.
The Adecco Group is making a strategic pivot into higher-margin HR and talent consulting through its LHH brand, a move analysts say could reshape its valuation narrative amid a challenging stock performance history.
Target's Michael Fiddelke and Walmart's John Furner step into the CEO role, outlining priorities to reinvigorate growth and customer loyalty amid operational and social challenges.
Facing pressure from both investors and regulators, banks and wealth managers are turning to pass-through voting mechanisms to reclaim shareholder influence and align stewardship with client values, even within passively managed funds.
The grocery sector begins 2026 with significant executive turnover, including leadership changes at Lidl US, The Save Mart Companies, and a major realignment within Walmart's top ranks ahead of its CEO transition.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
Goldman Sachs CEO David Solomon, while optimistic on global markets, forecasts a deliberate deceleration in talent acquisition for 2026 as the bank sharpens its focus on operational efficiency and strategic resource allocation.
Goldman Sachs Group (GS) has approved a significant dividend increase and projects a robust earnings outlook for Corporate America, fueling debate over whether its strong share price momentum has outpaced its fundamental valuation.
